G1 Phase
Latest Paper:
Phoebe S Lee,
Patricia W Greenwell,
Margaret Dominska,
Malgorzata Gawel,
Monica Hamilton,
Thomas D Petes
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America.
Homologous recombination is an important mechanism for the repair of DNA damage in mitotically dividing cells. Mitotic crossovers between homologues with heterozygous alleles can produce two homozygous daughter cells (loss of heterozygosity), whereas crossovers between repeated genes on non-homologous chromosomes can result in translocations. Using a genetic system that allows selection of daughter cells that contain the reciprocal products of mitotic crossing over, we mapped crossovers and gene conversion events at a resolution of about 4 kb in a 120-kb region of chromosome V of Saccharomyces cerevisiae. The gene conversion tracts associated with mitotic crossovers are much longer (averaging about 12 kb) than the conversion tracts associated with meiotic recombination and are non-randomly distributed along the chromosome. In addition, about 40% of the conversion events have patterns of marker segregation that are most simply explained as reflecting the repair of a chromosome that was broken in G1 of the cell cycle.
Most cited papers:
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA. abraham@burnham.org
Mesh-terms: ATP-Binding Cassette Transporters :: chemistry; ATP-Binding Cassette Transporters :: metabolism; Animals; Cell Cycle Proteins :: chemistry; Cell Cycle Proteins :: metabolism; DNA :: metabolism; Fungal Proteins :: chemistry; Fungal Proteins :: metabolism; G1 Phase; G2 Phase; Human; Mitosis; Models, Biological; Protein Structure, Tertiary; Protein-Serine-Threonine Kinases :: chemistry; Protein-Serine-Threonine Kinases :: metabolism; S Phase; Saccharomyces cerevisiae Proteins; Signal Transduction; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. ;
University of California, San Francisco, School of Medicine, Cancer Research Institute, 94143-0128, USA.
Mutations in the adenomatous polyposis coli (APC) tumour-suppressor gene occur in most human colon cancers. Loss of functional APC protein results in the accumulation of beta-catenin. Mutant forms of beta-catenin have been discovered in colon cancers that retain wild-type APC genes, and also in melanomas, medulloblastomas, prostate cancer and gastric and hepatocellular carcinomas. The accumulation of beta-catenin activates genes that are responsive to transcription factors of the TCF/LEF family, with which beta-catenin interacts. Here we show that beta-catenin activates transcription from the cyclin D1 promoter, and that sequences within the promoter that are related to consensus TCF/LEF-binding sites are necessary for activation. The oncoprotein p21ras further activates transcription of the cyclin D1 gene, through sites within the promoter that bind the transcriptional regulators Ets or CREB. Cells expressing mutant beta-catenin produce high levels of cyclin D1 messenger RNA and protein constitutively. Furthermore, expression of a dominant-negative form of TCF in colon-cancer cells strongly inhibits expression of cyclin D1 without affecting expression of cyclin D2, cyclin E, or cyclin-dependent kinases 2, 4 or 6. This dominant-negative TCF causes cells to arrest in the G1 phase of the cell cycle; this phenotype can be rescued by expression of cyclin D1 under the cytomegalovirus promoter. Abnormal levels of beta-catenin may therefore contribute to neoplastic transformation by causing accumulation of cyclin D1.
Mesh-terms: Binding Sites; Blotting, Western; Cell Division :: genetics; Colonic Neoplasms :: genetics; Consensus Sequence; Cyclin D1 :: genetics; Cytoskeletal Proteins :: genetics; Cytoskeletal Proteins :: physiology; G1 Phase; Gene Expression Regulation, Neoplastic; Hela Cells; Human; Luciferase :: genetics; Mutagenesis, Site-Directed; Promoter Regions (Genetics) ; Recombinant Fusion Proteins :: genetics; Reverse Transcriptase Polymerase Chain Reaction; Support, Non-U.S. Gov't; Trans-Activators; Transcription Factors :: metabolism; Transcription, Genetic; Tumor Cells, Cultured; ras Proteins :: physiology;
Department of Cell Biology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA.
Oscillations in the activity of cyclin-dependent kinases (CDKs) promote progression through the eukaryotic cell cycle. This review examines how proteolysis regulates CDK activity-by degrading CDK activators or inhibitors-and also how proteolysis may directly trigger the transition from metaphase to anaphase. Proteolysis during the cell cycle is mediated by two distinct ubiquitin-conjugation pathways. One pathway, requiring CDC34, initiates DNA replication by degrading a CDK inhibitor. The second pathway, involving a large protein complex called the anaphase-promoting complex or cyclosome, initiates chromosome segregation and exit from mitosis by degrading anaphase inhibitors and mitotic cyclins. Proteolysis therefore drives cell cycle progression not only by regulating CDK activity, but by directly influencing chromosome and spindle dynamics.
Mesh-terms: Anaphase; Animals; Cell Cycle; Cell Cycle Proteins :: metabolism; Cell Division; Cyclin-Dependent Kinases :: antagonists & inhibitors; Cyclin-Dependent Kinases :: metabolism; Cyclins :: metabolism; Enzyme Inhibitors :: metabolism; Fungal Proteins :: metabolism; Fungi :: cytology; Fungi :: metabolism; G1 Phase; Human; Ligases :: metabolism; Mitosis; Proteins :: metabolism; S Phase; Ubiquitin-Protein Ligase Complexes; Ubiquitin-Protein Ligases; Ubiquitins :: metabolism;
MRC Cell Mutation Unit, Sussex University, Falmer, Brighton BN1 9RR, UK. a.m.carr@sussex.ac.uk
Chk2 is a protein kinase that is activated in response to DNA damage and may regulate cell cycle arrest. We generated Chk2-deficient mouse cells by gene targeting. Chk2-/- embryonic stem cells failed to maintain gamma-irradiation-induced arrest in the G2 phase of the cell cycle. Chk2-/- thymocytes were resistant to DNA damage-induced apoptosis. Chk2-/- cells were defective for p53 stabilization and for induction of p53-dependent transcripts such as p21 in response to gamma irradiation. Reintroduction of the Chk2 gene restored p53-dependent transcription in response to gamma irradiation. Chk2 directly phosphorylated p53 on serine 20, which is known to interfere with Mdm2 binding. This provides a mechanism for increased stability of p53 by prevention of ubiquitination in response to DNA damage.
Mesh-terms: Animals; Apoptosis; DNA Damage; G1 Phase; G2 Phase; Gamma Rays; Gene Expression Regulation; Gene Targeting; Genes, Tumor Suppressor; Genes, p53; Human; Interphase; Mice; Phosphorylation; Phosphoserine :: metabolism; Protein Kinases; Protein p53 :: metabolism; Protein-Serine-Threonine Kinases :: metabolism; Proto-Oncogene Proteins :: metabolism; Stem Cells :: cytology; Stem Cells :: metabolism; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. ; T-Lymphocytes :: cytology; Transcription, Genetic;
G J Brunn,
C C Hudson,
A Sekulić,
J M Williams,
H Hosoi,
P J Houghton,
J C Lawrence Jr,
R T Abraham
Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
The immunosuppressant rapamycin interferes with G1-phase progression in lymphoid and other cell types by inhibiting the function of the mammalian target of rapamycin (mTOR). mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G1-phase progression in mammalian cells.
Mesh-terms: Androstadienes :: pharmacology; Animals; Carrier Proteins :: pharmacology; Cell Line; DNA-Binding Proteins :: pharmacology; Eukaryotic Initiation Factor-4E; G1 Phase; Heat-Shock Proteins :: pharmacology; Human; Insulin :: pharmacology; Peptide Initiation Factors :: metabolism; Phosphoproteins :: genetics; Phosphoproteins :: metabolism; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor):: antagonists & inhibitors; Phosphotransferases (Alcohol Group Acceptor):: metabolism; Polyenes :: pharmacology; Protein Kinases; Rats; Recombinant Proteins :: metabolism; Repressor Proteins :: genetics; Repressor Proteins :: metabolism; Signal Transduction; Sirolimus; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. ; Tacrolimus Binding Proteins; Transfection; Tumor Cells, Cultured;
Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, Tennessee 38105.
Murine D type cyclins associate with a catalytic subunit (p34PSK-J3) with properties distinct from known cyclin-dependent kinases (cdks). Mouse p34PSK-J3 shows less than 50% amino acid identity to p34cdc2, p33cdk2, and p36cdk3, lacks a PSTAIRE motif, and does not bind to p13suc1. Cyclin D1-p34PSK-J3 complexes accumulate in macrophages during G1 and decline in S phase, whereas complexes involving cyclins D2 and D3 form in proliferating T cells. Although histone H1 kinase activity is not detected in cyclin D or PSK-J3 immunoprecipitates, cyclin D-p34PSK-J3 complexes assembled in vitro stably bind and phosphorylate the retinoblastoma gene product (pRb) and an Rb-like protein (p107) but do not interact with pRb mutants that are functionally inactive. Thus, p34PSK-J3 is a cyclin D-regulated catalytic subunit that acts as an Rb (but not H1) kinase.
Mesh-terms: Amino Acid Sequence; Animals; Base Sequence; CDC2 Protein Kinase; Cells, Cultured; Cyclin D1; Cyclin-Dependent Kinases; Cyclins :: chemistry; G1 Phase; Human; Insects; Macrophages; Mice; Molecular Sequence Data; Oncogene Proteins :: chemistry; Protein Kinases :: chemistry; Protein Kinases :: genetics; Protein Kinases :: isolation & purification; Sequence Homology, Amino Acid; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. ;
The Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA. Lundberg@wi.mit.edu
The retinoblastoma protein (pRb) acts to constrain the G1-S transition in mammalian cells. Phosphorylation of pRb in G1 inactivates its growth-inhibitory function, allowing for cell cycle progression. Although several cyclins and associated cyclin-dependent kinases (cdks) have been implicated in pRb phosphorylation, the precise mechanism by which pRb is phosphorylated in vivo remains unclear. By inhibiting selectively either cdk4/6 or cdk2, we show that endogenous D-type cyclins, acting with cdk4/6, are able to phosphorylate pRb only partially, a process that is likely to be completed by cyclin E-cdk2 complexes. Furthermore, cyclin E-cdk2 is unable to phosphorylate pRb in the absence of prior phosphorylation by cyclin D-cdk4/6 complexes. Complete phosphorylation of pRb, inactivation of E2F binding, and activation of E2F transcription occur only after sequential action of at least two distinct G1 cyclin kinase complexes.
Mesh-terms: CDC2-CDC28 Kinases; Carrier Proteins; Cell Cycle Proteins :: metabolism; Cell Nucleus :: metabolism; Cells, Cultured; Cyclin E :: metabolism; Cyclin-Dependent Kinases :: metabolism; Cyclins :: metabolism; DNA-Binding Proteins :: metabolism; G1 Phase; Human; Phosphorylation; Protein-Serine-Threonine Kinases :: metabolism; Retinoblastoma Protein :: metabolism; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. ; Transcription Factors :: metabolism; Transfection;
Massachusetts General Hospital Cancer Center, Charlestown 02129.
The cellular protein p107 shares many structural and biochemical features with the retinoblastoma gene product, pRB. We have isolated a full-length cDNA for human p107 and have used this clone to study the function of p107. We show that, like pRB, p107 is a potent inhibitor of E2F-mediated trans-activation, and overexpression of p107 can inhibit proliferation in certain cell types, arresting sensitive cells in G1. Several experiments, however, showed that growth inhibition by pRB and p107 did not occur through the same mechanism. First, in the cervical carcinoma cell line C33A, p107 was able to block cell proliferation, whereas pRB could not, even though both proteins were potent inhibitors of E2F-mediated transcription in this cell line. Second, growth arrest by pRB and p107 was rescued differentially by various cell cycle regulators. Third, some mutants of p107 that cannot associate with adenovirus E1A were still able to inhibit cell proliferation, whereas analogous mutants in pRB are known to be unable to block cell growth. Together, these results suggest a biological role of p107 that is related, but not identical, to that of pRB.
Mesh-terms: Adenovirus E1A Proteins :: metabolism; Adenovirus E2 Proteins :: antagonists & inhibitors; Adenovirus E2 Proteins :: metabolism; Amino Acid Sequence; Animals; Base Sequence; Cell Division :: drug effects; Cloning, Molecular; DNA-Binding Proteins :: metabolism; Flow Cytometry; G1 Phase; Growth Inhibitors; Human; Molecular Sequence Data; Nuclear Proteins :: metabolism; Proteins :: chemistry; Proteins :: genetics; Proteins :: physiology; Repressor Proteins :: genetics; Repressor Proteins :: metabolism; Retinoblastoma Protein :: physiology; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Support, Non-U.S. Gov't; Trans-Activation (Genetics) ; Transcription, Genetic; Tumor Cells, Cultured;
Research Institute of Molecular Pathology, Vienna, Austria.
In eukaryotic cells, firing of DNA replication origins normally does not recur until after M phase. This characteristic is thought to be due to the properties of "initiation" proteins like Orc, Cdc6, and Mcms. Using formaldehyde cross-linking, we show that Cdc6p and Mcm7p associate specifically with replication origins during G1 but not during G2 in S. cerevisiae. Mcm7p's association with origins depends on Cdc6p. Ectopic expression of Cdc6p enables it to associate with origins during G2, but this fails to recruit Mcm7p. Our data suggest that the loading of Mcm proteins onto origins is regulated by two mechanisms: first, by Cdc6p occupancy, and second, by S- and M-CDKs, whose activity during S, G2, and M phases prevents Mcm loading.
Mesh-terms: Binding Sites; Cell Cycle Proteins :: metabolism; Cyclin-Dependent Kinases :: metabolism; DNA Replication; DNA-Binding Proteins :: metabolism; Fungal Proteins :: metabolism; G1 Phase; G2 Phase; Mitosis; Nuclear Proteins :: metabolism; Protein Binding; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Support, Non-U.S. Gov't;
Department of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
Cells deprived of serum mitogens will either undergo immediate cell cycle arrest or complete mitosis and arrest in the next cell cycle. The transition from mitogen dependence to mitogen independence occurs in the mid-to late G1 phase of the cell cycle and is called the restriction point. Murine Balb/c-3T3 fibroblasts deprived of serum mitogens accumulated the cyclin-dependent kinase (CDK) inhibitor p27Kip1. This was correlated with inactivation of essential G1 cyclin-CDK complexes and with cell cycle arrest in G1. The ability of specific mitogens to allow transit through the restriction point paralleled their ability to down-regulate p27, and antisense inhibition of p27 expression prevented cell cycle arrest in response to mitogen depletion. Therefore, p27 is an essential component of the pathway that connects mitogenic signals to the cell cycle at the restriction point.
Mesh-terms: 3T3 Cells; Amino Acid Sequence; Animals; Base Sequence; Cell Cycle Proteins; Culture Media; Cyclin-Dependent Kinases :: antagonists & inhibitors; Cyclin-Dependent Kinases :: metabolism; Cyclins :: metabolism; Down-Regulation; Enzyme Inhibitors :: metabolism; Epidermal Growth Factor :: pharmacology; G1 Phase; Gene Expression :: drug effects; Insulin-Like Growth Factor I :: pharmacology; Mice; Microtubule-Associated Proteins :: biosynthesis; Microtubule-Associated Proteins :: genetics; Microtubule-Associated Proteins :: metabolism; Mitogens :: pharmacology; Molecular Sequence Data; Oligonucleotides, Antisense :: pharmacology; Platelet-Derived Growth Factor :: pharmacology; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. ; Tumor Suppressor Proteins;
